ホームATBPF • OTCMKTS
add
Antibe Therapeutics Ord Shs
市場ニュース
財務情報
損益計算書
収益
純利益
| (CAD) | 2023年12月info | 前年比変化率 |
|---|---|---|
収益 | — | — |
営業費用 | 459.60万 | -1.42% |
純利益 | -421.30万 | 2.39% |
純利益率 | — | — |
1 株当たりの収益 | -0.08 | 0.50% |
EBITDA | — | — |
実効税率 | — | — |
貸借対照表
総資産
負債総額
| (CAD) | 2023年12月info | 前年比変化率 |
|---|---|---|
現金および短期投資 | 2490.60万 | -41.20% |
総資産 | 5636.20万 | -23.56% |
負債総額 | 3042.50万 | -0.13% |
純資産 | 2593.70万 | — |
発行済み株式 | 5266.54万 | — |
帳簿価格 | 0.44 | — |
総資産利益率 | -19.71% | — |
資本利益率 | -41.30% | — |
キャッシュ フロー
現金の純増減額
| (CAD) | 2023年12月info | 前年比変化率 |
|---|---|---|
純利益 | -421.30万 | 2.39% |
営業キャッシュ フロー | -384.50万 | -6.66% |
投資キャッシュ フロー | 1104.10万 | 1,975.38% |
財務キャッシュ フロー | — | — |
現金の純増減額 | 719.60万 | 334.09% |
フリー キャッシュ フロー | -246.88万 | -2,419.13% |
概要
Antibe Therapeutics was a Toronto-based pharmaceutical company that develops pain and inflammation-reducing drugs based on gaseous mediator technology. Antibe was founded by John L. Wallace, also a co-founder of NicOx, the first company to develop drugs utilizing gaseous mediators. Founded in 2009, the company listed on the TSX Venture Exchange in 2013 and was moved to the Toronto Stock Exchange in November 2020. In 2015, Antibe acquired Citagenix, a distributor involved in regenerative medicine.
On June 1, 2020, the company announced positive results in the final Phase 2 trial of its first drug Otenaproxesul.
On March 29, 2021, the drug's Investigational New Drug application was cleared by the US Food and Drug Administration, allowing for human trials.
In May 2024 the company went bankrupt and its stock was delisted from the Toronto Stock Exchange. Wikipedia
設立
2009
ウェブサイト
従業員数
11
